Targeting PDAC metabolism: Environment determines what has GOT2 give.
Where this comes from
- Record sourced from PubMed, PMID 36323232.
- Also identified by DOI 10.1016/j.cmet.2022.09.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic disruption is a mainstay of cancer therapy, prompting research aimed at identifying novel metabolic targets. Despite strong effects observed in culture, three recent studies found pancreatic tumors are refractory to disruption of the metabolic enzyme GOT2, revealing complex interactions within the tumor microenvironment that bypass its conventional metabolic roles.
Medical subject headings
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms